PDMR Notification

Argent Biopharma Limited

30 April 2024

 

30 April 2024

Argent BioPharma Ltd

PDMR Notification

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 68,000 unlisted options. This notification is made in accordance the UK Market Abuse Regulations.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Amir Polak
2	Reason for the notification
(a)	Position		Chief Pharmaceutical Development Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		Argent BioPharma Ltd
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b)	Identification Code (ISIN)		AU0000326647
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		12,000	N/A
	Aggregated information
	AUD	0.00		12,000	N/A
(e)	Date of transaction		26 April 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yair Tal
2	Reason for the notification
(a)	Position		Chief Information Security Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		Argent BioPharma Ltd
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b)	Identification Code (ISIN)		AU0000326647
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		8,000	N/A
	Aggregated information
	AUD	0.00		8,000	N/A
(e)	Date of transaction		26 April 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yifat Steuer
2	Reason for the notification
(a)	Position		Chief Operating Officer and Deputy CEO
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		Argent BioPharma Ltd
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b)	Identification Code (ISIN)		AU0000326647
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		15,000	N/A
	Aggregated information
	AUD	0.00		15,000	N/A
(e)	Date of transaction		26 April 2024
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Itay Nissim
2	Reason for the notification
(a)	Position		Chief Supply Chain Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		Argent BioPharma Ltd
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b)	Identification Code (ISIN)		AU0000326647
(c)	Nature of transaction		Grant of Options over Ordinary Shares
(d)	Currency	Price		Volume	Total
	AUD	0.00		12,000	N/A
	Aggregated information
	AUD	0.00		12,000	N/A
(e)	Date of transaction		26 April 2024
(f)	Place of transaction		Outside a trading venue

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Limited                Roby Zomer CEO & Managing Director [phone] [e-mail]	Argent BioPharma Limited Rowan Harland Company Secretary [phone] [e-mail]
UK IR/PR Advisers  IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [phone] [e-mail]	UK Brokers Oberon Capital Aimee McCusker / Adam Pollock [phone] [e-mail] [e-mail]

About Argent BioPharma

Argent BioPharma purpose is to address unmet medical needs through the pioneering integration of Nanotechnology and Multidisciplinary research methods. Our approach heralds a transformative shift in healthcare, combining the power of multi-targeted drug therapies with precision nanoscale delivery to enhance treatment efficacy while reducing side effects. Central to our ethos is making these innovative treatments accessible, ensuring they reach those underserved by current medical solutions. As we endeavor to become globally recognized in the life science industry, we are committed to bridging healthcare gaps, redefining industry standards, and providing impactful solutions and hope to communities worldwide.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

END